- Procedures to restore blood flow to the affected legs of peripheral artery disease (PAD) patients stopped progression of the scarring associated with the disease.
- Muscle scarring increased in PAD patients who did not receive intervention or received supervised exercise.
- Procedures that restored blood flow to the legs and exercise therapy were associated with increased maximum distance that PAD patients were able to walk on a treadmill.
Embargoed until 3 p.m. CT / 4 p.m. ET, Thursday, May 5, 2016
NASHVILLE, Tennessee, May 5, 2016 — Restoring blood flow to the legs of patients with peripheral artery disease (PAD) may stop the progression of scarring in their leg muscles, according to preliminary research presented at the American Heart Association’s Arteriosclerosis, Thrombosis and Vascular Biology / Peripheral Vascular Disease 2016 Scientific Sessions.
PAD causes pain and fatigue while walking due to poor blood circulation in arteries that supply blood to the limbs. The decreased blood flow can lead to substantial scarring and damage in leg muscles. Moreover, there are currently no available treatments once the scarring has occurred. Supervised exercise therapy and revascularization procedures (which reopen or bypass blockages in the blood vessels) may help PAD patients walk further and longer, but it is not known if these treatments affect the scarring process.
Researchers looked at levels of transforming growth factor-beta (TGF-β1) — a protein that promotes scarring — and the amount of collagen (tough protein fibers found in scars) in calf muscle biopsies from patients with PAD severe enough to be considered for surgery. Six months later, they compared changes in biopsy results among 20 patients who underwent revascularization, 19 who participated in a supervised exercise program, and 17 who had no treatment. Among the findings:
- Scarring factors – collagen fibers and TGF-β1 – increased in the exercise and control groups, but not in the revascularization group;
- Patients in both the revascularization and exercise groups increased their maximum walking time on treadmill, before calf pain made it impossible to continue;
- Only patients in the revascularization group improved the distance they could walk in six minutes.
Neither exercise nor revascularization treatment reversed scarring that had already taken place in the calf muscles. However, “increasing blood flow to the leg with revascularization procedures halted the progression of scarring and allowed the patients to walk longer and further,” said Duy Ha, B.S., lead author of the study and a doctoral candidate in cellular and integrative physiology at the University of Nebraska Medical Center in Omaha. “This suggests that the long-term benefits to the health of leg muscles is better with revascularization than with exercise therapy alone. Unfortunately, not all patients are candidates for these procedures, which carry significant risks, and the treated vessels may get blocked again,”
“We hope that we can develop therapies that directly decrease TGF-β1 and its associated scarring in the leg muscles of PAD patients. Such new treatments, when used alone or along with revascularization and exercise, may maintain or enhance the ability of our patients to walk and live healthy lives,” Ha said.
Co-authors are George Casale, Ph.D.; Alicia Luis; Kevin Harkins; Reagan Huber; Tanmayee Changalasetty, Ruby Hickman; Mina Hanna, M.S.; Stanley Swanson, B.S.; Holly DeSpiegelaere, R.N.; and Iraklis Pipinos, M.D. Author disclosures are on the abstract.
This study is funded by the National Heart Lung and Blood Institute, National Institute of Aging, and the Charles and Mary Heider Fund for Excellence in Vascular Surgery. The V.A. Nebraska and Western Iowa Health Care System provided additional support.
Note: Meeting presentation time is 6 p.m. CT, Thursday, May 5th, 2016.
- The American Heart Association’s Peripheral Artery Disease site
- Daily Science News from the ATVB meeting
- Follow the news on @HeartNews Twitter #ATVBPVDScience and check out all the news and information across AHA/ASA social media on our Social Media Hub.
Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding.
For media inquiries about this news release and AHA spokesperson perspective:
Darcy Spitz: (212) 878-5940; email@example.com
Julie Del Barto (national broadcast): (214) 706-1330; firstname.lastname@example.org
For general media inquiries:
American Heart Association Communications: (214) 706-1173
For public inquiries:
Life is why, science is how . . . we help people live longer, healthier lives.